As part of his Ph.D. in pharmacy at Université Laval, Dr. Audet-Walsh focused on the link between steroid hormones and endometrial and prostate cancers. During his work, he has demonstrated that the regulation of steroid metabolism is altered in tumor cells, notably via alterations of specific metabolic pathways. In addition, several pharmacogenomic analyses have been able to establish the link between genetic markers in steroidogenesis genes in relationship with prostate cancer progression. He then undertook a postdoctoral fellowship at McGill University, where he studied transcriptional regulation mechanisms by members of the nuclear receptor family using transcriptomic, cistromic (functional genomic) and metabolomic tools in different in vitro and in vivo models, with a particular interest in the regulation of energy metabolism. Dr. Audet-Walsh has notably demonstrated the interaction between several nuclear receptors and different cell signaling pathways in the transcriptional control of cell metabolism following various stresses. In addition, he was interested in characterizing the different waves of transcriptional regulation that involve the functional interaction between different families of transcription factors, especially in hormone-sensitive cancers.

Recently recruited at the Centre de recherche du CHU de Québec – Laval University, Dr. Audet-Walsh specializes in the study of metabolic reprogramming in hormone-sensitive cancers, by nuclear receptors. By their actions, these receptors act as master regulators of the cellular bioenergetic pathways, necessary for both the synthesis of ATP and the biosynthesis of macromolecules that are essential to cell proliferation. By using transcriptomic, cistromic and metabolomic analyzes, he wants to understand how these receptors contribute to the transcriptional regulation of different cellular metabolic pathways in physiology and disease. In addition, he also wants to understand how metabolism in turn influences hormonal signaling, since several metabolic intermediates are essential for the regulation of the epigenome. Finally, a translational research approach targeting the key elements of metabolism in pathological conditions will be used to validate its results in a context of in vitro (cells in culture) and in vivo (rodent models, human samples) models. Understanding the metabolic reprogramming associated with pathological conditions, as well as the factors that control such reprogramming, will allow the identification of new therapeutic targets in different hormone-sensitive cancers.

CHUL
2705 Boulevard Laurier
R-4714
Québec, QC
Canada G1V 4G2
31 entries « 4 of 4 »

Audet-Walsh E, Lachaud AA, Anderson A

The CYP2B2 5' flank contains a complex glucocorticoid response unit.

Journal Article

Biochem Pharmacol, 76 (10), pp. 1298-306, 2008, ISSN: 0006-2952.

Abstract | Links:

31 entries « 4 of 4 »
Signaler des ajouts ou des modifications

Active projects

  • Bourse de soutien aux nouveaux détenteurs de Chaire de recherche du Canada, Subvention, Université Laval - Soutien à la recherche, Fonds de soutien aux professeurs-chercheurs bénéficiant d’une Chaire de recherche du Canada, from 2020-07-01 to 2022-06-30
  • Canada Research Chair in Targeting metabolic vulnerabilities for the treatment of hormone-sensitive cancers, Subvention, Secrétariat des programmes interorganismes à l’intention des établissements, Chaires de recherche du Canada - Fonctionnement, from 2020-07-01 to 2025-06-30
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
  • Functional interaction between the androgen and the estrogen signalling pathways in prostate cancer, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-10-01 to 2023-03-31
  • Génomique fonctionnelle des récepteurs aux hormones stéroïdiennes dans le contrôle du métabolisme énergétique des cellules de cancer de la prostate, Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2019-07-01 to 2023-06-30
  • Génomique fonctionnelle des récepteurs aux hormones stéroïdiennes dans le contrôle du métabolisme énergétique des cellules de cancer de la prostate, Subvention, Fonds de recherche du Québec - Santé, Établissement de jeunes chercheurs - Juniors 1, from 2019-07-01 to 2023-06-30
  • Inhibition of the AMPK metabolic program for the treatment of prostate cancer, Subvention, L'Institut de recherche de la Société canadienne du cancer, Subventions pour l'innovation, from 2019-08-01 to 2022-07-31
  • Regulation of Cellular Energy Metabolism in Mammary Epithelial Cells, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2019-04-01 to 2024-03-31

Recently finished projects

  • Deciphering the role of KLF5 and NFYA in prostate cancer, Subvention, Société de recherche sur le cancer, Subvention de fonctionnement, from 2018-09-01 to 2020-08-31
  • Programme de soutien aux nouveaux professeurs de la Faculté de médecine, Subvention, Université Laval - démarrage nouveau chercheur, Soutien facultaire aux jeunes chercheurs de la Faculté de médecine, from 2017-07-01 to 2019-06-30
  • Regulation of Cellular Energy Metabolism in Mammary Epithelial Cells, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Supplément Tremplin vers la découverte, from 2019-04-01 to 2020-03-31
  • Targeting metabolic vulnerabilities for the treatment of prostate cancer, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds des leaders John-R.-Evans (FLJR), from 2019-07-01 to 2020-12-31
  • Targeting the estrogen signaling pathway to treat prostate cancer, Subvention, American Association for Cancer Research, from 2018-12-01 to 2019-11-30
Data provided by the Université Laval research projects registery